6533b82cfe1ef96bd12900e5
RESEARCH PRODUCT
Kawasaki disease: Guidelines of Italian Society of Pediatrics, part II - Treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks
Elisabetta StrafaceMaya El HachemIsabella Tarissi De JacobisGrazia BossiFabrizio De BenedettiElisabetta CortisSusanna EspositoGiulia MarucciAlberto VillaniFabio CardinaleAlessandro RiminiUgo GiordanoSabrina BuonuomoRosa Maria DellepianeAndrea ZorziWalter MalorniLivio D’isantoRossella MassaroMaria Cristina MaggioPatrizia SaliceGiovanni CorselloChristian PescosolidoDonatella PietraforteAlessandra MarchesiMarzia DuseMaria Cristina PietrograndeSavina MannarinoFernanda FalciniSilvana MartinoDomenico Del PrincipeAurelio SecinaroDonato RiganteGian Luigi Marsegliasubject
MaleDrug ResistanceReviewCoronary Artery Disease030204 cardiovascular system & hematologySeverity of Illness IndexCoronary artery diseaseEfficacy0302 clinical medicineCardiovascular Diseasecoronary artery abnormalitiesChildCoronary artery abnormalitieSocieties MedicalPediatricAnti-Inflammatory Agents Non-Steroidallcsh:RJ1-570Immunoglobulins IntravenousSettore MED/38Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICACardiovascular DiseasesInnovative biotechnologieChild PreschoolPractice Guidelines as TopicFemaleRisk assessmentmedicine.drugHumanmedicine.medical_specialtypediatricsMucocutaneous Lymph Node SyndromeRisk AssessmentFollow-Up Studie03 medical and health sciencesinnovative biotechnologies030225 pediatricsDiabetes mellitusSeverity of illnessmedicineHumansIntensive care medicineIntravenous immunoglobulinAspirinKawasaki diseasebusiness.industryWarfarinlcsh:Pediatricsmedicine.diseasePersonalized medicineInfliximabAspirin; Child; Coronary artery abnormalities; Innovative biotechnologies; Intravenous immunoglobulin; Kawasaki disease; Personalized medicine;Immunoglobulins IntravenouPediatrics Perinatology and Child Healthperinatology and child healthKawasaki diseaseaspirin; child; coronary artery abnormalities; innovative biotechnologies; intravenous immunoglobulin; Kawasaki disease; personalized medicine; pediatrics perinatology and child healthbusinessFollow-Up Studiesdescription
Abstract This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to prompt diagnosis and most appropriate treatment of KD resistant forms and cardiovascular complications, including non-pharmacologic treatments, follow-up, lifestyle and prevention of cardiovascular risks in the long-term through a set of 17 recommendations. Guidelines, however, should not be considered a norm that limits the treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient’s condition, and disease severity or individual complications.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-08-30 |